File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

TitleMYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Authors
Issue Date2013
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
Citation
Blood, 2013, v. 121 n. 20, p. 4021-4031 How to Cite?
AbstractDiffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on gene expression signatures. In this study, we analyzed 893 de novo DLBCL patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). We show that MYC/BCL2 protein coexpression occurred significantly more commonly in the ABC subtype. Patients with the ABC or GCB subtype of DLBCL had similar prognoses with MYC/BCL2 coexpression and without MYC/BCL2 coexpression. Consistent with the notion that the prognostic difference between the 2 subtypes is attributable to MYC/BCL2 coexpression, there is no difference in gene expression signatures between the 2 subtypes in the absence of MYC/BCL2 coexpression. DLBCL with MYC/BCL2 coexpression demonstrated a signature of marked downregulation of genes encoding extracellular matrix proteins, those involving matrix deposition/remodeling and cell adhesion, and upregulation of proliferation-associated genes. We conclude that MYC/BCL2 coexpression in DLBCL is associated with an aggressive clinical course, is more common in the ABC subtype, and contributes to the overall inferior prognosis of patients with ABC-DLBCL. In conclusion, the data suggest that MYC/BCL2 coexpression, rather than cell-of-origin classification, is a better predictor of prognosis in patients with DLBCL treated with R-CHOP.
Persistent Identifierhttp://hdl.handle.net/10722/181756
ISSN
2019 Impact Factor: 17.543
2015 SCImago Journal Rankings: 6.395
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHu, S-
dc.contributor.authorXu-Monette, ZY-
dc.contributor.authorTzankov, A-
dc.contributor.authorGreen, T-
dc.contributor.authorWu, L-
dc.contributor.authorBalasubramanyam, A-
dc.contributor.authorLiu, WM-
dc.contributor.authorVisco, C-
dc.contributor.authorLi, Y-
dc.contributor.authorMiranda, RN-
dc.contributor.authorMontes-Moreno, S-
dc.contributor.authorDybkaer, K-
dc.contributor.authorChiu, A-
dc.contributor.authorOrazi, A-
dc.contributor.authorZu, Y-
dc.contributor.authorBhagat, G-
dc.contributor.authorRichards, KL-
dc.contributor.authorHsi, ED-
dc.contributor.authorChoi, WWL-
dc.contributor.authorZhao, X-
dc.contributor.authorvan Krieken, JH-
dc.contributor.authorHuang, Q-
dc.contributor.authorHuh, J-
dc.contributor.authorAi, W-
dc.contributor.authorPonzoni, M-
dc.contributor.authorFerreri, AJM-
dc.contributor.authorZhou, F-
dc.contributor.authorSlack, GW-
dc.contributor.authorGascoyne, RD-
dc.contributor.authorTu, M-
dc.contributor.authorVariakojis, D-
dc.contributor.authorChen, W-
dc.contributor.authorGo, RS-
dc.contributor.authorPiris, MA-
dc.contributor.authorMøller, MB-
dc.contributor.authorMedeiros, LJ-
dc.contributor.authorYoung, KH-
dc.date.accessioned2013-03-19T03:56:06Z-
dc.date.available2013-03-19T03:56:06Z-
dc.date.issued2013-
dc.identifier.citationBlood, 2013, v. 121 n. 20, p. 4021-4031-
dc.identifier.issn0006-4971-
dc.identifier.urihttp://hdl.handle.net/10722/181756-
dc.description.abstractDiffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on gene expression signatures. In this study, we analyzed 893 de novo DLBCL patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). We show that MYC/BCL2 protein coexpression occurred significantly more commonly in the ABC subtype. Patients with the ABC or GCB subtype of DLBCL had similar prognoses with MYC/BCL2 coexpression and without MYC/BCL2 coexpression. Consistent with the notion that the prognostic difference between the 2 subtypes is attributable to MYC/BCL2 coexpression, there is no difference in gene expression signatures between the 2 subtypes in the absence of MYC/BCL2 coexpression. DLBCL with MYC/BCL2 coexpression demonstrated a signature of marked downregulation of genes encoding extracellular matrix proteins, those involving matrix deposition/remodeling and cell adhesion, and upregulation of proliferation-associated genes. We conclude that MYC/BCL2 coexpression in DLBCL is associated with an aggressive clinical course, is more common in the ABC subtype, and contributes to the overall inferior prognosis of patients with ABC-DLBCL. In conclusion, the data suggest that MYC/BCL2 coexpression, rather than cell-of-origin classification, is a better predictor of prognosis in patients with DLBCL treated with R-CHOP.-
dc.languageeng-
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/-
dc.relation.ispartofBlood-
dc.titleMYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program-
dc.typeArticle-
dc.identifier.emailChoi, WWL: choiwl@hkucc.hku.hk-
dc.identifier.authorityChoi, WWL=rp00247-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1182/blood-2012-10-460063-
dc.identifier.pmid23449635-
dc.identifier.pmcidPMC3709650-
dc.identifier.scopuseid_2-s2.0-84879385620-
dc.identifier.hkuros213553-
dc.identifier.volume121-
dc.identifier.issue20-
dc.identifier.spage4021-
dc.identifier.epage4031-
dc.identifier.isiWOS:000321871900006-
dc.publisher.placeUnited States-
dc.identifier.issnl0006-4971-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats